ARTICLE | Clinical News
Memantine Phase III results
February 22, 2000 8:00 AM UTC
Merz (Frankfurt, Germany) said it saw positive results in a 252-patient U.S. Phase III trial of Memantine NMDA receptor modulator to treat Alzheimer's disease. The compound was licensed from Neurobiol...